We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $980M
1-Year Est. Return 470.8%
This Fund
S&P 500
This Quarter Est. Return
+59.01%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$720M
AUM Growth
-$21.6M
Cap. Flow
-$169M
Cap. Flow %
-23.52%
Top 10 Hldgs %
49.7%
Holding
103
New
21
Increased
18
Reduced
27
Closed
35

Top Buys

Rank Stock Value
1
CELC icon
Celcuity
CELC
+$23.5M
2
IMNM icon
Immunome
IMNM
+$19.8M
3
KALV
KalVista Pharmaceuticals
KALV
+$14.1M
4
COGT icon
Cogent Biosciences
COGT
+$12.1M
5
PFE icon
Pfizer
PFE
+$10.6M

Top Sells

Rank Stock Value
1
RNAM
Avidity Biosciences
RNAM
+$36.8M
2
AKRO
Akero Therapeutics
AKRO
+$30.6M
3
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$24.8M
4
INSM icon
Insmed
INSM
+$24.7M
5
CDTX
Cidara Therapeutics
CDTX
+$21.2M

Sector Composition

Rank Sector Weight
1 Healthcare 95.99%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GH icon
26
Guardant Health
GH
$19.1B
$9.39M 1.3%
+91,914
New +$8.22M
ORIC icon
27
Oric Pharmaceuticals
ORIC
$1.17B
$9.13M 1.27%
1,116,604
-832,204
-43% -$9.58M
PCVX icon
28
Vaxcyte
PCVX
$7.65B
$6.87M 0.95%
148,787
-165,552
-53% -$7.4M
TRVI icon
29
Trevi Therapeutics
TRVI
$2.57B
$6.78M 0.94%
541,240
-47,549
-8% -$550K
GOSS icon
30
Gossamer Bio
GOSS
$101M
$6.62M 0.92%
2,135,722
-2,643,360
-55% -$7.54M
SYRE icon
31
Spyre Therapeutics
SYRE
$8.5B
$6.15M 0.85%
+187,737
New +$4.91M
LXEO icon
32
Lexeo Therapeutics
LXEO
$338M
$6.13M 0.85%
617,608
-161,003
-21% -$1.47M
AMLX icon
33
Amylyx Pharmaceuticals
AMLX
$2.19B
$6.12M 0.85%
506,242
-193,758
-28% -$2.63M
CERS icon
34
Cerus
CERS
$575M
$5.8M 0.81%
2,814,383
+98,597
+4% +$171K
CMPX icon
35
Compass Therapeutics
CMPX
$349M
$5.65M 0.78%
1,051,343
-1,782,645
-63% -$8.23M
SLNO
36
DELISTED
Soleno Therapeutics
SLNO
$5.44M 0.76%
+117,485
New +$6.44M
CGEN icon
37
Compugen
CGEN
$212M
$5.32M 0.74%
3,479,805
+168,640
+5% +$280K
CLDX icon
38
Celldex Therapeutics
CLDX
$2.94B
$5.19M 0.72%
191,074
-157,848
-45% -$4.16M
OLMA icon
39
Olema Pharmaceuticals
OLMA
$977M
$5.16M 0.72%
206,280
-727,261
-78% -$12.9M
ERAS icon
40
Erasca
ERAS
$6.15B
$4.9M 0.68%
1,317,584
-50,491
-4% -$142K
KALV
41
CALL
DELISTED
KalVista Pharmaceuticals
KALV
$4.69M 0.65%
+290,600
New +$3.85M
FULC icon
42
Fulcrum Therapeutics
FULC
$241M
$4.46M 0.62%
+394,650
New +$4.02M
FULC icon
43
CALL
Fulcrum Therapeutics
FULC
$241M
$4.43M 0.62%
+391,900
New +$3.99M
AARD
44
Aardvark Therapeutics
AARD
$116M
$3.99M 0.55%
303,939
-2,973
-1% -$37.1K
CCCC icon
45
C4 Therapeutics
CCCC
$389M
$3.81M 0.53%
1,994,224
+96,841
+5% +$229K
SRZN icon
46
Surrozen
SRZN
$223M
$3.56M 0.49%
+157,323
New +$2.55M
CTNM
47
Contineum Therapeutics
CTNM
$538M
$3.52M 0.49%
307,540
+141,379
+85% +$1.61M
MLYS icon
48
Mineralys Therapeutics
MLYS
$2.32B
$3.45M 0.48%
94,983
+14,983
+19% +$601K
RLAY icon
49
Relay Therapeutics
RLAY
$4B
$3.37M 0.47%
+398,167
New +$2.84M
ABEO icon
50
Abeona Therapeutics
ABEO
$355M
$3.31M 0.46%
627,738
-367,016
-37% -$1.85M
1
2
3 4 5

Similar funds

BIP
Blueprint Investment Partners Greensboro, North Carolina $980M AUM 27.19% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $977M AUM 19.09% 1-Year Est. Return
FCM
Fortis Capital Management Bellevue, Washington $977M AUM 17.17% 1-Year Est. Return
PE
PSG Equity Boston, Massachusetts $977M AUM 13.39% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
GFP
Gryphon Financial Partners Columbus, Ohio $976M AUM 23.05% 1-Year Est. Return
ADIC
Abu Dhabi Investment Council Abu Dhabi, United Arab Emirates $975M AUM

Silverarc Capital Management's Q4 2025 Portfolio in Review

As of Q4 2025, Silverarc Capital Management held 103 positions worth $720M, down 2.9% from $742M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Silverarc Capital Management withdrew a net $169M in Q4 2025, closing 35 positions and reducing 27 holdings. Its most notable exit was Avidity Biosciences, an estimated $36.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 93% a quarter earlier.

Against the trend, Silverarc Capital Management opened a new position in Immunome worth $24.2M.

  • Silverarc Capital Management's largest Q4 2025 buy was Immunome: 1,126,210 shares worth $24.2M.
  • Silverarc Capital Management added most to Celcuity in Q4 2025, an estimated $23.5M increase.
  • Silverarc Capital Management's biggest Q4 2025 reduction was Rhythm Pharmaceuticals, cutting an estimated $24.8M.
  • Silverarc Capital Management fully exited Avidity Biosciences in Q4 2025, selling an estimated $36.8M.
  • Silverarc Capital Management's ten largest holdings make up 50% of its $720M portfolio in Q4 2025.
  • Silverarc Capital Management opened 21 new positions and closed 35 in Q4 2025.
  • Silverarc Capital Management's portfolio value fell 2.9% quarter-over-quarter to $720M.

Based on Silverarc Capital Management's 13F filing for Q4 2025, filed 12 Feb 2026.